The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, “ATTR-CM,” that has become a battleground for companies like Pfizer, Alnylam and BridgeBio.

Original title: “Immutrin raises $87M to advance drug for progressive heart disease”

Like its pharma peers, Novartis is pouring money into Chinese operations, including expansions and upgrades at an existing manufacturing facility.

Original title: “Novartis Pledges $480M To Expand China Presence, Following Eli Lilly and AstraZeneca”

Aardvark Therapeutics’ obesity asset is based on its lead molecule, which in February was linked to reversible heart safety signals in a healthy volunteer study.

Original title: “Aardvark Pauses 2 Obesity Trials, Reveals New Details on Cardiac Concerns”

Gilead’s median employee compensation in 2025 was $238,979. Daniel O’Day’s compensation package is 119 times larger.

Original title: “Gilead Chief Gets 20% Pay Bump, Still Falls Short of $30M Club”

Following last month’s $7.8 billion purchase of CAR T biotech Arcellx, Gilead’s dealmaking train chugs along with yet another acquisition—this time securing Ouro Medicines’ pipeline of T cell engagers for inflammatory diseases.

Original title: “Gilead Drops $2.1B for Ouro, Hopes To Split Cost with Galapagos”

Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and “autologous” approach, stood out amongst the crowd.

Original title: “How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup”

DNA Script has signed distribution agreements with Gencell, Bio-Medical Science (BMS) and Biostream, expanding global access to its SYNTAX platform.

Original title: “DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream”

Qlaris Bio has appointed Fred Guerard as president and CEO. Guerard will also join the Board of Directors.

Original title: “Qlaris Bio appoints Fred Guerard as President and CEO”

The biotech industry needs to stop waiting for a rebound. The pandemic changed everything, though not in the ways most people think.

Original title: “Biotechs Must Face Reality To Succeed in Today’s Funding Environment”

Healthcare investor Kevin Tang and his allies now hold almost every leadership position at Aurinia Pharmaceuticals, the company at the heart of former CDER Director George Tidmarsh’s exit from the FDA.

Original title: “Tang Seizes Control of Aurinia, Taking CEO Post in Total Transformation of C-Suite”

Industry executives can share their views on the “national priority” program at a June meeting. Elsewhere, Sanofi licensed a T cell engager and Acorda’s former CEO resurfaced at a cell therapy startup.

Original title: “FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares”

IsomAb has appointed Dr Philip Brainin as CEO and member of the Board of Directors.

Original title: “IsomAb appoints Philip Brainin as CEO”

Kali Therapeutics’ T cell engager, for which Sanofi is initially paying $180 million, could potentially be developed for a range of B cell–driven autoimmune disorders.

Original title: “Sanofi Keeps Immuno Deals Coming With Kali Bet Worth Potential $1B+”

By Shahmir Ahmed, Alp Ceylan, and Francesco del Sesto (Bocconi University); Diana Usova, Dylan Stiassny, Oli Cedar, Obianuju Okafor (University of Bristol)Photo: Volodymyr Hryshchenko (Unsplash)Summary of IPOAs the pharmaceutical industry looks to artificial intelligence to accelerate drug ... By Shahmir Ahmed, Alp Ceylan, and Francesco del Sesto (Bocconi University); Diana Usova, Dylan Stiassny, Oli Cedar, Obianuju Okafor (University of Bristol)Photo: Volodymyr Hryshchenko (Unsplash)Summary of IPOAs the pharmaceutical industry looks to artificial intelligence to accelerate drug discovery, Generate Biomedicines are positioning themselves as a force to be reckoned with in this growing market. Generate Biomedicines listed on the NASDAQ, and raised $400mn, representing the largest biotech IPO of 2026, to date. $300mn of the proceeds are expected to bankroll the completion of Phase 3 trials for the company’s lead candidate, GB-0895, which seeks to treat severe asthma. Remaining funds will be directed to additional research and development for potential new product candidates. A significant portion of these funds will be allocated to the Phase 3 clinical trials of its lead candidate GB-0895, a treatment targeting severe asthma, as well as to other programs in immunology, oncology, and respiratory diseases. The public listing also strengthens Generate Biomedicines’ ability to scale its technology platform and deepen collaborations with large pharmaceutical partners. The company already maintains strategic partnerships with major industry players, including Amgen and Novartis, which together represent potential multi-billion-dollar collaboration agreements aimed at developing AI-designed biologic drugs. Ahead of its listing, Generate Biomedicines attracted significant investor attention due to strong backing from venture firm Flagship Pioneering and prominent biotechnology investors. The company priced its IPO at $16 per share, the midpoint of its proposed $15-$17 range, selling 25 million shares and raising approximately $400 million.

Original title: “Generate Biomedicines’ IPO”

Earendil Labs’ AI-centered platform has produced more than 40 programs, including anti-inflammatory assets that have attracted a pair of partnership agreements with Sanofi.

Original title: “Backed by Sanofi, Pfizer, Earendil Bags $787M for AI-Driven Biologics Design”